Senseonics (NYSE:SENS) Shares Up 8.4% - What's Next?

Senseonics Holdings, Inc. (NYSE:SENS - Get Free Report)'s share price shot up 8.4% during mid-day trading on Friday . The stock traded as high as $1.12 and last traded at $1.10. 4,920,939 shares changed hands during mid-day trading, a decline of 78% from the average session volume of 22,190,742 shares. The stock had previously closed at $1.01.

Analysts Set New Price Targets

SENS has been the topic of several recent research reports. StockNews.com initiated coverage on shares of Senseonics in a report on Thursday, December 26th. They set a "sell" rating on the stock. HC Wainwright reiterated a "buy" rating and issued a $2.00 target price on shares of Senseonics in a research note on Friday, November 15th.

Senseonics Trading Up 11.9 %

The business's 50-day moving average price is $0.50 and its 200 day moving average price is $0.42. The firm has a market capitalization of $672.72 million, a price-to-earnings ratio of -8.69 and a beta of 0.64. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38.

Senseonics (NYSE:SENS - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.01). Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. The firm had revenue of $4.26 million during the quarter, compared to analysts' expectations of $4.02 million. On average, equities analysts forecast that Senseonics Holdings, Inc. will post -0.14 earnings per share for the current fiscal year.

Remove Ads

Insider Buying and Selling at Senseonics

In other news, CFO Frederick T. Sullivan purchased 124,933 shares of the company's stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $0.38 per share, with a total value of $47,474.54. Following the transaction, the chief financial officer now owns 2,478,844 shares in the company, valued at approximately $941,960.72. The trade was a 5.31 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Timothy T. Goodnow acquired 315,000 shares of Senseonics stock in a transaction that occurred on Tuesday, December 10th. The shares were purchased at an average price of $0.31 per share, for a total transaction of $97,650.00. Following the completion of the purchase, the chief executive officer now directly owns 11,310,355 shares of the company's stock, valued at $3,506,210.05. The trade was a 2.86 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Senseonics

Several institutional investors have recently modified their holdings of SENS. FMR LLC increased its stake in shares of Senseonics by 48,267.2% during the third quarter. FMR LLC now owns 168,318 shares of the company's stock valued at $59,000 after acquiring an additional 167,970 shares during the period. Ridgecrest Wealth Partners LLC acquired a new position in shares of Senseonics during the 4th quarter valued at $60,000. GSA Capital Partners LLP bought a new stake in shares of Senseonics in the 3rd quarter worth $117,000. Symmetry Partners LLC acquired a new stake in shares of Senseonics in the third quarter valued at $164,000. Finally, Cubist Systematic Strategies LLC boosted its stake in Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company's stock valued at $166,000 after buying an additional 85,501 shares in the last quarter. Institutional investors own 12.36% of the company's stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.